US Edition
Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment - Cardiac Interventions Today
July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the safety and potential efficacy of multiorgan denervation (MDN) in patients with uncontrolled hypertension (HTN). According to the company, the SPYRAL GEMINI pilot program is intended to evaluate the feasibility of combined denervation of both the renal and common hepatic arteries with the company’s Symplicit…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
